Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 09 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital271 Beijing Tiantan Hospital219 Cancer Institute and Hospital, Chinese Academy of Medical Sciences205 AstraZeneca191 Peking University People's Hospital166
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Beijing

5576 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Hefei TG ImmunoPharma Co., Ltd.
Phase 1
123
Beijing
2024-01-03
Recruiting
Peking University Cancer Hospital & Institute
Phase 2
111
Beijing
2024-01-01
Recruiting
Beijing Friendship Hospital
Not applicable
226
Beijing
2024-01-01
Recruiting
Peking University Cancer Hospital & Institute
Early Phase 1
50
Beijing
2024-01-01
Recruiting
Tian Hua
Observational
12,000
Beijing
2024-01-01
By invitation
Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)
NCT06959784Diabetes Mellitus, Cardiovascular Diseases, Cerebrovascular Disease
DrugsMetformin·Semaglutide
China-Japan Friendship Hospital
Phase 4
142
Beijing
2024-01-01
Recruiting
MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT
NCT06748690Gastrointestinal Stromal Tumor of Stomach, Submucosal Tumor of Stomach
Peking University People's Hospital
Not applicable
96
Beijing
2024-01-01
Recruiting
Haplo-HSCT for Myelofibrosis
NCT06674382Myelofibrosis
Peking University People's Hospital
Not applicable
39
Beijing
2024-01-01
Recruiting
Peking University Third Hospital
Observational
1,000
Beijing
2024-01-01
Recruiting
Peking Union Medical College Hospital
Observational
300
Beijing
2024-01-01
Not yet open
China National Study of Adrenal Venous Sampling
NCT06192238Hyperaldosteronism
Chinese Academy of Medical Sciences, Fuwai Hospital
Observational
1,500
Beijing, Chongqing, Xiamen, Lanzhou, Foshan, Guangzhou, Shenzhen, Nanning
2024-01-01
Recruiting
Xuanwu Hospital, Beijing
Observational
165
Beijing
2024-01-01
By invitation
Peking University Third Hospital
Observational
335
Beijing
2024-01-01
Not yet open
Modified Laparoscopic Transcystic Biliary Drainage in the Management of Cholecystocholedocholithiasis
NCT06011941Common Bile Duct Calculi, Acute; Cholecystitis, Choledocholithiasis, Acute Cholecystitis With Obstruction, Acute Cholangitis
Peking University Third Hospital
Not applicable
310
Beijing
2024-01-01
By invitation
Beijing Tiantan Hospital
Observational
750
Beijing
2024-01-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
300
Beijing
2024-01-01
Recruiting
Beijing Hospital of Integrated Traditional Chinese and Western Medicine
Not applicable
102
Beijing
2024-01-01
Recruiting
Shanghai Chest Hospital
Not applicable
100
Zhengzhou, Beijing, Chengdu, Linyi, Nanchang, Shanghai, Shijiazhuang, Zhejiang
2024-01-01
Recruiting
Peking Union Medical College Hospital
Observational
300
Beijing
2024-01-01
Recruiting
Beijing Tsinghua Chang Gung Hospital
Observational
120
Beijing
2024-01-01
Recruiting
B7-H3 NIR Imaging for Osteosarcoma Surgery
NCT06778603Osteosarcoma, Resection Margins, B7-H3 Probe, Local Recurrence
Peking University People's Hospital
Phase 1/2
32
Beijing
2024-01-01
Recruiting
China-Japan Friendship Hospital
Observational
800
Beijing
2024-01-01
Recruiting
SHUANG ZHENG JIA, PhD
Not applicable
50
Beijing
2024-01-01
Recruiting
Peking University
Phase 1
20
Beijing
2024-01-01
Recruiting
LivQ-box® Parameters in the Diagnosis of Liver Inflammation
NCT06802731Liver Inflammation, Fatty Liver Disease
Wuxi Hisky Medical Technology Co Ltd
Observational
365
Beijing
2024-01-01
Recruiting
Peking University First Hospital
Observational
3,000
Beijing
2024-01-01
By invitation
Beijing Chao Yang Hospital
Not applicable
160
Beijing
2024-01-01
Recruiting
Cerebral Microembolization Associated With PFO Closure
NCT06347276Thrombosis Cardiac, Atrial Septal Defect, Patent Foramen Ovale (PFO)
China National Center for Cardiovascular Diseases
Observational
800
Beijing
2024-01-01
Recruiting
Chinese PLA General Hospital
Observational
1,500
Beijing
2024-01-01
Recruiting
Standardized Study Protocol of Percutaneous Vertebroplasty Based on Pedicle Nine-Grid Zoning Method
NCT07616583Osteoporotic Vertebral Compression Fractures, Vertebroplasty
Beijing Friendship Hospital
Not applicable
68
Beijing
2024-01-01
Recruiting
Microfracture With Platelet Rich Plasma Gel Injection for Osteochondral Lesion of the Talus
NCT06358807Osteochondral Lesion of Talus, Microfractures, Platelet Rich Plasma
Peking University Third Hospital
Not applicable
70
Beijing
2024-01-01
Recruiting
Peking Union Medical College Hospital
Observational
3,000
Beijing
2024-01-01
By invitation
Hypofractionated Radiotherapy for HNSCC in Elderly Patients
NCT06768125Head and Neck Cancer Squamous Cell Carcinoma, ELDERLY PEOPLE, Hypofractionation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
51
Beijing
2024-01-01
Recruiting
Peking Union Medical College Hospital
Observational
1,000
Beijing
2024-01-01
Recruiting
Efficacy and Safety of Photodynamic Therapy for CIN3
NCT07009327Precancerous Cervical Lesion
Peking University Third Hospital
Not applicable
100
Beijing
2024-01-01
Recruiting
Chinese PLA General Hospital
Observational
2,000
Beijing
2024-01-01
Recruiting
Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT
NCT06130579Myeloid Leukemia, Myelodysplastic Syndromes
DrugIFN-α
Peking University People's Hospital
Phase 2
35
Beijing
2024-01-01
Recruiting
Peking Union Medical College Hospital
Not applicable
100
Beijing
2024-01-01
Active, closed
Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer
NCT06215677Colon Cancer, Mismatch Repair Deficiency, Immunotherapy
DrugCamrelizumab
Peking Union Medical College Hospital
Phase 2
18
Beijing
2024-01-01
Recruiting
China-Japan Friendship Hospital
Phase 1/2
200
Beijing
2024-01-01
Recruiting
Peking University Third Hospital
Observational
330
Beijing
2024-01-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
133
Beijing
2024-01-01
Recruiting
Peking University First Hospital
Observational
3,000
Beijing
2024-01-01
Recruiting
Glofitamab in Chinese Patients With R/R DLBCL
NCT06481826DLBCL - Diffuse Large B Cell Lymphoma
DrugGlofitamab
Peking Union Medical College Hospital
Observational
20
Beijing
2024-01-01
Not yet open
Jing Liu
Phase 4
92
Beijing
2024-01
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
69
Beijing
2024-01
Recruiting
Ruimin Wang
Phase 1
20
Beijing
2024-01
Recruiting
Chongqing Precision Biotech Co., Ltd
Phase 1
24
Beijing
2023-12-31
Active, closed
Merck Sharp & Dohme LLC
Phase 3
340
Bengbu, Hefei, Beijing, Quanzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou
2023-12-31
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,310
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Wuhan, Changsha
2023-12-31
Recruiting
Off-the-shelf CD123 CAR-NK for R/R AML
NCT06201247Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Peking University People's Hospital
Early Phase 1
12
Beijing
2023-12-30
Recruiting
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease
NCT06189495Systemic Sclerosis Associated Interstitial Lung Disease, Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD), Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
DrugGenSci048
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 2
30
Beijing, Wuhan, Jinan, Chengdu
2023-12-30
Recruiting
Daiichi Sankyo
Phase 3
250
Beijing, Fujian, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang
2023-12-30
Recruiting
Bristol-Myers Squibb
Phase 1/2
460
Beijing, Guangzhou, Zhengzhou, Suzhou, Nanchang, Shenyang, Qingdao, Shanghai
2023-12-29
Active, closed
Shanghai Weihe Medical Laboratory Co., Ltd.
Observational
16,666
Beijing, Changchun, Guangzhou, Hangzhou, Shenyang
2023-12-28
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
185
Beijing
2023-12-28
Not yet open
Relmacabtagene Autoleucel in Hematologic Malignancies
NCT06142188Lymphoma, B-Cell, Large B-cell Lymphoma, Follicular Lymphoma
DrugsRelmacabtagene Autoleucel·Relma-cel
Shanghai Ming Ju Biotechnology Co., Ltd.
Observational
150
Beijing
2023-12-28
Recruiting
Teligene US
Phase 2
66
Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Jinan
2023-12-27
Active, closed
Sanofi
Phase 3
943
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Harbin, Jiazhuang
2023-12-27
Recruiting
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1/2
110
Beijing, Hangzhou, Jinan, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an
2023-12-26
By invitation
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM
NCT06616727Recurrent Glioblastoma Multiforme (GBM)
Shanghai Simnova Biotechnology Co.,Ltd.
Phase 1
50
Beijing
2023-12-26
Recruiting
Hinova Pharmaceuticals Inc.
Phase 1/2
84
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Guiyang, Zhengzhou
2023-12-26
Recruiting
Fujian Akeylink Biotechnology Co., Ltd.
Phase 2
45
Beijing
2023-12-26
Active, closed
Study of Human Bone Marrow Mesenchymal Stem Cells in APAP
NCT06111846Autoimmune Pulmonary Alveolar Proteinosis
Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
Phase 2
10
Beijing
2023-12-25
Recruiting
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
NCT06177041Locally Advanced Unresectable or Metastatic Gastric Cancer, Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsCapecitabine·Oxaliplatin
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Phase 3
486
Beijing
2023-12-25
Recruiting
Qilu Pharmaceutical Co., Ltd.
Phase 3
270
Bengbu, Bozhou, Hefei, Beijing, Fuzhou, Dalian, Shanghai, Changzhi
2023-12-25
Active, closed
Beijing Chest Hospital
Phase 3
186
Beijing, Changsha, Hefei, Jiamusi, Shandong, Xi'an, Xinxiang, Shijiazhuang
2023-12-22
Recruiting
Bivision Pharmaceuticals, Inc.
Phase 1/2
90
Hefei, Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Suzhou, Wuxi
2023-12-22
Active, closed
Bristol-Myers Squibb
Phase 3
190
Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-12-21
Recruiting
Eli Lilly and Company
Phase 3
1,264
Beijing, Changchun, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou
2023-12-21
Active, closed
AstraZeneca
Observational
409
Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Nanning, Guiyang, Shijiazhuang
2023-12-20
Recruiting
Ascentage Pharma Group Inc.
Phase 3
400
Hefei, Beijing, Fuzhou, Foshan, Guangzhou, Nanning, Zhengzhou, Wuhan
2023-12-20
Recruiting
Janssen Research & Development, LLC
Phase 1
300
Beijing, Hangzhou, Tianjin
2023-12-20
Recruiting
Dongguan TT Medical
Not applicable
280
Beijing
2023-12-20
Not yet open
Convalife (Shanghai) Co., Ltd.
Phase 2
98
Beijing
2023-12-20
Recruiting
Shandong Suncadia Medicine Co., Ltd.
Phase 1/2
146
Beijing, Guangzhou
2023-12-20
Active, closed
AbbVie
Phase 3
614
Beijing, Guangzhou, Wuhan, Xi'an, Jinan, Shanghai, Chengdu, Tianjin
2023-12-19
Recruiting
Zhongda Hospital
Not applicable
188
Beijing, Nanjing
2023-12-19
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
324
Bengbu, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Dalian
2023-12-19
Recruiting
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
NCT06014190Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
DrugHS-20089
Hansoh BioMedical R&D Company
Phase 2
460
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang
2023-12-18
Recruiting
Hansoh BioMedical R&D Company
Phase 2
170
Hefei, Beijing, Fuzhou, Guangzhou, Zhuhai, Nanning, Harbin, Zhengzhou
2023-12-18
Recruiting
Peking Union Medical College Hospital
Not applicable
102
Beijing
2023-12-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,314
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Wuhan, Changsha, Nanjing
2023-12-18
Recruiting
Peking Union Medical College Hospital
Observational
33
Beijing
2023-12-15
Recruiting
A Study of YL202 in Selected Patients With Advanced Solid Tumors
NCT06107686NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors
DrugYL202 should be infused
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shantou, Guilin
2023-12-15
Recruiting
Peking University Third Hospital
Not applicable
50
Beijing
2023-12-15
Recruiting
Merck Sharp & Dohme LLC
Phase 3
614
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Zhanjiang, Shijiazhuang, Harbin
2023-12-15
Recruiting
AstraZeneca
Phase 3
1,145
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dongwan, Fuzhou
2023-12-14
Recruiting
ALI/ARDS Clinical Sub-phenotyping Study
NCT06123962Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
China-Japan Friendship Hospital
Observational
1,500
Beijing
2023-12-14
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Hefei, Beijing, Chongqing, Guangzhou, Liuzhou, Nanning, Guiyang, Haikou
2023-12-13
Active, closed
Sanofi
Phase 3
1,655
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou
2023-12-13
Active, closed
Xuanwu Hospital, Beijing
Not applicable
38
Beijing
2023-12-12
Recruiting
HTA Co., Ltd.
Phase 3
184
Beijing
2023-12-12
Active, closed
Lynk Pharmaceuticals Co., Ltd
Phase 3
430
Beijing
2023-12-12
Active, closed
Hoffmann-La Roche
Phase 3
1,050
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2023-12-11
Recruiting
Tianjin Chest Hospital
Not applicable
800
Beijing, Lanfang, Tianjin
2023-12-11
Recruiting
Chinese Occupational Population Cohort of Lifestyle and Physical Fitness (LiFitChina)
NCT06275009Lifestyle, Physical Fitness, Cardiovascular Diseases
China National Center for Cardiovascular Diseases
Observational
18,512
Beijing
2023-12-11
Recruiting
AbbVie
Phase 3
110
Beijing, Guangzhou, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2023-12-11
Recruiting
Cell Energy Life Sciences Group Co. LTD
Phase 1/2
150
Beijing, Shenzhen, Shijiazhuang
2023-12-10
Recruiting
Peking Union Medical College Hospital
Not applicable
1,224
Beijing
2023-12-08
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
178
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Luoyang
2023-12-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
710
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang, Nanning
2023-12-06
Recruiting
AstraZeneca
Phase 1/2
226
Beijing, Changsha, Guangzhou, Shenyang
2023-12-05
Recruiting
Chinese SLE Treatment And Research Group
Observational
100
Beijing
2023-12-05
Active, closed
AstraZeneca
Phase 3
760
Beijing, Changchun, Changsha, Chengdu, Deyang, Fuzhou, Guangzhou, Guiyang
2023-12-04
Recruiting
Beijing Hospital
Phase 2
296
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Hohhot, Shenyang
2023-12-02
Recruiting
An Exploratory Study of Focal Pulse Ablation System in the Treatment of Atrial Arrhythmia
NCT06157437Typical Atrial Flutter, Atrial Fibrillation (AF)
Hangzhou Dinova EP Technology Co., Ltd
Not applicable
10
Beijing
2023-12-01
Recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.
Not applicable
290
Beijing, Chongqing, Changsha, Nanjing, Suzhou, Shanghai, Xi’an, Chengdu
2023-12-01
Recruiting
NV-001 in the Treatment of Advanced Solid Tumors
NCT06051760Malignant Neoplasm
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
20
Beijing
2023-12-01
Not yet open
Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement
NCT06131489Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus, Bowel Resection
Beijing Friendship Hospital
Observational
20
Beijing
2023-12-01
By invitation
Beijing Ditan Hospital
Not applicable
180
Beijing
2023-12-01
Active, closed
AstraZeneca
Phase 3
64
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Ha’erbin, Jinan
2023-12-01
Recruiting
Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC
NCT06170710Head and Neck Squamous Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
173
Beijing
2023-12-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
1,384
Beijing, Shanghai, Chengdu
2023-12-01
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant
BeOne Medicines
Phase 1
433
Beijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shenyang, Shanghai
2023-12-01
Recruiting
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3
400
Guangzhou, Shanghai, Anyang, Baoding, Beijing, Changchun, Changde, Changsha
2023-12-01
Recruiting
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
NCT06799637Advanced Solid Tumors, Pancreatic Carcinoma, Ovarian Cancer, Cervical Cancers
DrugXNW28012
Evopoint Biosciences Inc.
Phase 1/2
350
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Guiyang, Baoding, Harbin
2023-12-01
By invitation
Normal Chinese Lifespan Brain Charts Initiative (NCLBCI)
NCT06643858Healthy, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, Neurodegenerative Diseases
Beijing Tiantan Hospital
Observational
10,000
Beijing
2023-12-01
Not yet open
A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.
NCT06142617Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation
DrugsOsimertinib·Pemetrexed·Keytruda
Peking Union Medical College Hospital
Phase 2
37
Beijing
2023-12-01
Recruiting
Ruijin Hospital
Phase 2
30
Beijing, Guangzhou, Henan, Shanghai, Wuhan
2023-11-30
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
366
Beijing
2023-11-30
Recruiting
Peking University
Phase 2
54
Beijing
2023-11-28
Active, closed
Chronic Kidney Disease Registry Platform Study
NCT06117852Chronic Kidney Diseases
AstraZeneca
Observational
5,000
Baotou, Beijing, Changsha, Changzhou, Chengdu, Chongqing, Dongguan, Guangzhou
2023-11-28
Recruiting
RemeGen Co., Ltd.
Phase 2
90
Beijing, Fuzhou, Kunming, Xiamen, Wuwei, Guangzhou, Harbin, Zhengzhou
2023-11-27
Recruiting
NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI
NCT05638867Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome
DrugsRivaroxaban·Clopidogrel·Aspirin
China National Center for Cardiovascular Diseases
Phase 4
3,944
Beijing
2023-11-25
By invitation
Shanghai Henlius Biotech
Phase 1
367
Beijing, Changsha
2023-11-24
Recruiting
AstraZeneca
Phase 3
625
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2023-11-23
Active, closed
AstraZeneca
Phase 3
1,898
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Guilin
2023-11-21
Active, closed
TransThera Sciences (Nanjing), Inc.
Phase 2
50
Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Harbin, Zhengzhou
2023-11-17
Recruiting
Amgen
Phase 3
750
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2023-11-16
Recruiting
Tasly Pharmaceutical Group Co., Ltd
Phase 3
480
Beijing, Changsha, Chengdu, Haerbin, Huizhou, Kaifeng, Luoyang, Luzhou
2023-11-16
Active, closed
Beijing Tiantan Hospital
Not applicable
224
Beijing
2023-11-16
Recruiting
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2/3
166
Beijing, Hangzhou
2023-11-16
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
376
Beijing
2023-11-16
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
756
Harbin, Changsha, Nanchang, Shenyang, Jinan, Anyang, Beijing, Changchun
2023-11-15
Recruiting
Beijing Scitech-Mq Pharmaceuticals Limited
Phase 2
60
Beijing
2023-11-15
Active, closed
AstraZeneca
Phase 3
1,902
Beijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin
2023-11-14
Not yet open
Akeso
Phase 3
642
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Zhangzhou, Lanzhou
2023-11-14
Recruiting
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 3
162
Beijing, Xiamen, Guangzhou, Shenzhen, Guilin, Shijiazhuang, Xinxiang, Nanchang
2023-11-13
Recruiting
Takeda
Phase 3
80
Beijing, Guangzhou, Shenzhen, Shanghai, Tianjin
2023-11-13
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2023-11-12
Active, closed
BeOne Medicines
Phase 3
652
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Jieyang, Nanning, Nanyang
2023-11-11
Active, closed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
50
Beijing
2023-11-11
Recruiting
Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population
NCT06096909Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome, Lipid Lowering, Vascular Inflammation
DrugTafolecimab
China National Center for Cardiovascular Diseases
Phase 4
3,684
Beijing, Tangshan
2023-11-11
Not yet open
Safety and Efficacy Study of Implantable Neuromodulation for Poststroke Hemiplegia
NCT06121947Stroke Sequelae, Deep Brain Stimulation, Vagus Nerve Stimulation, Motor Recovery
Chinese PLA General Hospital
Not applicable
98
Beijing
2023-11-10
Recruiting
Xuesong Li
Observational
90
Beijing
2023-11-10
Active, closed
China-Japan Friendship Hospital
Observational
12
Beijing
2023-11-10
Active, closed
AstraZeneca
Phase 3
863
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Kunming, Lanzhou
2023-11-09
Active, closed
Evaluate the Safety, Tolerability of BAT6026
NCT06094179Dermatitis, Atopic
Bio-Thera Solutions
Phase 1/2
33
Beijing
2023-11-09
Active, closed
AstraZeneca
Phase 3
314
Beijing, Guangzhou, Hangzhou, Lanzhou, Shanghai, Tianjin
2023-11-08
Active, closed
Pfizer
Phase 3
1,571
Beijing, Fuzhou, Guangzhou, Guiyang, Shijiazhuang, Nanyang, Wuhan, Changsha
2023-11-08
Active, closed
A Study of ST-1898 for Unresectable or Metastatic Melanoma
NCT06359860Unresectable or Metastatic Melanoma
DrugST-1898
Beijing Scitech-Mq Pharmaceuticals Limited
Phase 1/2
64
Beijing
2023-11-07
Recruiting
Personalized KSX01-TCRT in Patients With Advanced Solid Tumors
NCT06150365Refractory Solid Tumors, Relapsed Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early Phase 1
12
Beijing
2023-11-07
Active, closed
Bristol-Myers Squibb
Phase 2
227
Beijing, Guangzhou, Luoyang, Changsha, Hangzhou
2023-11-07
Active, closed
AstraZeneca
Phase 3
1,835
Baotou, Beijing, Changsha, Chengdu, Chongqing, Deyang, Foshan, Guangzhou
2023-11-07
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
130
Beijing
2023-11-06
Recruiting
Shanghai Kechow Pharma, Inc.
Phase 3
165
Beijing
2023-11-02
Recruiting
A Study to Test Tetrandrine Tablets for Connective Tissue Disease-Related Lung Disease
NCT07319598Interstitial Lung Disease (ILD), Connective Tissue Disease-associated Interstitial Lung Disease
Peking University Third Hospital
Phase 4
100
Beijing
2023-11-02
Recruiting
Disease Characteristics of IR-CAD: a Case-control Study
NCT06007248Coronary Artery Disease, Coronary Artery Stenosis, Coronary Artery Restenosis, Coronary Artery Disease Progression
Peking Union Medical College Hospital
Observational
30
Beijing
2023-11-02
Active, closed
Heidelberg University
Observational
600
Beijing
2023-11-01
Recruiting
Peking University Third Hospital
Observational
120
Beijing
2023-11-01
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
40
Beijing
2023-11-01
Active, closed
Beijing Tsinghua Chang Gung Hospital
Observational
918
Beijing
2023-11-01
Not yet open
Radial Artery Versus No-touch Saphenous Vein
NCT06014047Coronary Artery Disease
China National Center for Cardiovascular Diseases
Not applicable
774
Beijing
2023-11-01
Active, closed
Peking University Third Hospital
Not applicable
146
Beijing
2023-11-01
Recruiting
Aneurysmal Subarachnoid Hemorrhage Multi-Omics Research Program
NCT07270419Aneurysmal Subarachnoid Hemorrhage
Xiaolin Chen, MD
Observational
2,000
Beijing
2023-11-01
Recruiting
Peking University Cancer Hospital & Institute
Phase 2
116
Beijing
2023-11-01
Recruiting
Mao Jianhua
Phase 3
140
Wuhan, Nanjing, Kunming, Hangzhou, Ningbo, Wenzhou, Beijing, Shanghai
2023-11-01
Recruiting
Peking Union Medical College Hospital
Phase 2
22
Beijing
2023-11-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
170
Beijing, Guangzhou, Jinan
2023-11-01
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
376
Beijing
2023-10-31
Recruiting
App and Body Fat Scale in the Management of Overweight Patients
NCT05866107Schizophrenia, Bipolar Disorder, Metabolic Syndrome, Overweight and Obesity
Capital Medical University
Not applicable
204
Beijing
2023-10-31
Recruiting
LeonaBio
Phase 3
600
Anhui, Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqicun
2023-10-31
Active, closed
Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus
NCT05749874PreDiabetes, Abdominal Obesity, Hypertension, Dyslipidemias
DrugBerberine
China National Center for Cardiovascular Diseases
Phase 4
2,024
Beijing
2023-10-31
Not yet open
Beijing Tiantan Hospital
Observational
20,000
Beijing
2023-10-30
Recruiting
Geneplus-Beijing Co. Ltd.
Observational
60
Beijing, Shanghai
2023-10-30
Recruiting
Fu Wai Hospital, Beijing, China
Phase 4
252
Beijing
2023-10-30
Recruiting
Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
NCT06190067Relapsed Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
DrugAzacitidine
Navy General Hospital, Beijing
Phase 2
40
Beijing
2023-10-30
Recruiting
Allist Pharmaceuticals, Inc.
Phase 2
88
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-10-27
Active, closed
Vigonvita Life Sciences
Phase 1
82
Beijing
2023-10-27
Recruiting
OriCell Therapeutics Co., Ltd.
Phase 1/2
83
Hangzhou, Beijing, Nanjing, Shanghai, Wuhan
2023-10-26
Active, closed
Broadenbio Ltd., Co.
Phase 1
42
Beijing
2023-10-26
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,109
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Huizhou
2023-10-25
Recruiting
Shanghai Kechow Pharma, Inc.
Phase 3
165
Beijing
2023-10-25
Active, closed
Peking University Cancer Hospital & Institute
Phase 2
20
Beijing
2023-10-25
Active, closed
Bristol-Myers Squibb
Phase 3
1,057
Hefei, Beijing, Lanzhou, Guangzhou, Shenzhen, Shenzhen Shi, Zhengzhou, Shijiazhuang
2023-10-25
Recruiting
The Correlation Between Ovarian Function and Serum Biomarkers
NCT06096766Premature Ovarian Insufficiency, Diminished Ovarian Reserve, Biomarker, Copper
Shi Yun
Observational
35
Beijing
2023-10-25
Active, closed
AstraZeneca
Phase 3
895
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2023-10-24
Active, closed
Different Dose Esketamine and Dexmedetomidine Combination for Supplemental Analgesia After Scoliosis Correction Surgery
NCT06062550Scoliosis Correction, Esketamine, Dexmedetomidine, Postoperative Analgesia
DrugEsketamine
Peking University First Hospital
Phase 4
312
Beijing
2023-10-24
Recruiting
Beijing Tiantan Hospital
Observational
48
Beijing
2023-10-24
Recruiting
Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
NCT06176729Diffuse Large B Cell Lymphoma
Yan Zhang, MD
Phase 2
30
Beijing
2023-10-24
Active, closed
Bristol-Myers Squibb
Phase 3
402
Hefei, Beijing, Chongqing, Xiamen, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2023-10-24
Recruiting
Hoffmann-La Roche
Phase 3
182
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Shanghai
2023-10-22
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
342
Wuhu, Beijing, Xiamen, Guangzhou, Shenzhen, Guiyang, Haikou, Luoyang
2023-10-20
Recruiting
Xuanwu Hospital, Beijing
Not applicable
80
Beijing
2023-10-20
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
180
Beijing, Fuzhou, Zhengzhou, Changsha, Nanjing, Nanchang, Changchun, Jinan
2023-10-19
Active, closed
China-Japan Friendship Hospital
Observational
94
Beijing
2023-10-19
Recruiting
Pan Xiangbin
Not applicable
120
Beijing
2023-10-18
Recruiting
Neuracle Medical Technology(Shanghai) Co.,Ltd.
Not applicable
9
Beijing, Shanghai
2023-10-17
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
120
Beijing
2023-10-16
Active, closed
China National Center for Cardiovascular Diseases
Not applicable
2,700
Beijing
2023-10-15
Active, closed
Janssen Research & Development, LLC
Phase 3
684
Beijing, Bengbu, Chengde, Chengdu, Jiaxing, Jinan, Nanchang, Nanyang
2023-10-12
Recruiting
Chinese PLA General Hospital
Phase 1/2
30
Beijing
2023-10-11
Recruiting
AbbVie
Phase 3
1,500
Beijing, Chongqing, Guangzhou, Shenzhen, Wuhan, Nanchang, Changchun, Xi'an
2023-10-11
Recruiting
Sanofi
Phase 3
180
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wuxi
2023-10-10
Recruiting
Peking Union Medical College
Not applicable
150
Beijing
2023-10-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
14,550
Hefei, Beijing, Chongqing, Foshan, Guangzhou, Huizhou, Jiangmen, Shenzhen
2023-10-09
Recruiting
CARsgen Therapeutics Co., Ltd.
Phase 1
30
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guanzhou, Hangzhou, Shanghai
2023-10-08
Active, closed
AstraZeneca
Phase 3
5,511
Baoding, Beijing, Bengbu, Binzhou, Cangzhou, Changchun, Changsha, Chengdu
2023-10-05
Recruiting
Pfizer
Phase 4
80
Beijing, Guangzhou, Jinan, Hangzhou
2023-10-03
By invitation
Biogen
Phase 3
306
Beijing, Shenzhen, Dongguan, Guangzhou, Changsha, Nanjing, Shanghai, Kunming
2023-10-03
Recruiting
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
Phase 1
300
Beijing
2023-10-01
Recruiting
68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC
NCT06277180Medullary Thyroid Cancer, Prositron Emission Tomography, Fibroblast Activation Protein Inhibitor, Surgery
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
50
Beijing
2023-10-01
Recruiting
China-Japan Friendship Hospital
Phase 4
114
Beijing
2023-10-01
Recruiting
Beijing Tongren Hospital
Phase 2
100
Beijing
2023-10-01
Recruiting
Peking University Third Hospital
Not applicable
200
Beijing
2023-10-01
Recruiting
Peking Union Medical College Hospital
Not applicable
60
Beijing
2023-10-01
Recruiting
Effect of Transpulmonary MP on Prognosis of Patients With Severe ARDS Treated With VV-ECMO
NCT06062212Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation, Mechanical Power, Transpulmonary Mechanical Power
Beijing Chao Yang Hospital
Observational
100
Beijing
2023-10-01
Recruiting
Peking Union Medical College Hospital
Observational
100
Beijing
2023-10
Recruiting
Beijing 302 Hospital
Phase 1/2
150
Beijing
2023-09-30
Recruiting
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
NCT06023784Left Bundle Branch Area Pacing, Right Ventricular Pacing, Atrioventricular Block, Atrial Fibrillation
Peking Union Medical College Hospital
Not applicable
530
Beijing
2023-09-30
Recruiting
Tris-CAR-T Cell Therapy for Recurrent Glioblastoma
NCT05577091Recurrent Glioblastoma
Beijing Tiantan Hospital
Phase 1
10
Beijing
2023-09-30
Recruiting
China-Japan Friendship Hospital
Observational
150
Beijing
2023-09-29
Recruiting
Suzhou Abogen Biosciences Co., Ltd.
Phase 1/2
218
Beijing, Guangzhou, Nanning, Shanxi, Shenzhen
2023-09-28
Recruiting
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 2
56
Beijing, Chongqing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Chengdu, Hangzhou
2023-09-28
Recruiting
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Phase 4
320
Beijing
2023-09-27
Recruiting
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2
100
Beijing
2023-09-27
Active, closed
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
Adcentrx Therapeutics
Phase 1
144
Beijing, Fujian, Guangzhou, Hunan, Jinan, Shanghai, Wuhan
2023-09-26
Recruiting
Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
NCT05968053Carotid Artery Stenosis, Glioma, Intracranial Aneurysm, Intracranial Hemorrhages
Beijing Tiantan Hospital
Observational
500
Beijing
2023-09-25
Recruiting
Hexaell Biotech Co., Ltd.
Phase 1/2
92
Beijing
2023-09-22
Recruiting
Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
NCT06023758HER2-positive Locally Advanced Resectable Gastric Cancer
DrugsKN046·KN026·Xelox
Peking University
Phase 2
18
Beijing
2023-09-22
Recruiting
AstraZeneca
Phase 3
800
Beijing, Changde, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou
2023-09-22
Active, closed
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
990
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Foshan, Guangzhou
2023-09-22
Recruiting
Taizhou Mabtech Pharmaceutical Co.,Ltd
Phase 4
30
Beijing
2023-09-21
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
165
Beijing, Lanzhou, Tangshan, Shanghai, Tianjin
2023-09-21
Active, closed
Moderately Hypofractionated Adaptive Radiotherapy for Cervical Cancer
NCT05994300Cervical Neoplasm, Adaptive Radiotherapy, Radiotherapy; Adverse Effect
Peking Union Medical College Hospital
Not applicable
30
Beijing
2023-09-19
Recruiting
Recurrent High Grade Glioma Treated by LITT
NCT06161610Recurrent High Grade Glioma
Beijing Tiantan Hospital
Not applicable
135
Beijing, Guangzhou, Zhengzhou, Wuhan, Changchun, Shenyang, Jinan, Shanghai
2023-09-19
Active, closed
Hoffmann-La Roche
Phase 3
1,130
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangdong Province Guangzhou City, Guangzhou
2023-09-18
Recruiting
Extracranial-intracranial Bypass Surgery for Symptomatic Chronic Middle Cerebral Artery Occlusion: the CMOSS-2 Trial
NCT05899582Symptomatic Chronic Middle Cerebral Artery Occlusion, Infarction, Middle Cerebral Artery
Xuanwu Hospital, Beijing
Not applicable
420
Beijing
2023-09-15
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2
40
Beijing
2023-09-15
Recruiting
RemeGen Co., Ltd.
Phase 1/2
221
Anhui, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2023-09-14
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
120
Lu'an, Beijing, Fuzhou, Xiamen, Wuwei, Shenzhen, Liuzhou, Yulin
2023-09-14
Active, closed
Hoffmann-La Roche
Phase 3
687
Baoji, Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou
2023-09-14
Active, closed
Bristol-Myers Squibb
Phase 3
1,255
Hefei, Beijing, Guangzhou, Shenzhen, Shenzhen Shi, Zhengzhou, Shijiazhuang, Yichang Shi
2023-09-14
Recruiting
Peking Union Medical College Hospital
Not applicable
30
Beijing
2023-09-13
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
DrugBelimumab
GlaxoSmithKline
Phase 2/3
300
Beijing, Changchun, Chengdu, Luzhou, Mianyang, Nanjing, Nanning, Shanghai
2023-09-13
By invitation
argenx
Phase 3
240
Guangzhou, Nanjing, Beijing, Chengdu, Shanghai, Shenyang, Zhengzhou
2023-09-12
Recruiting
Peking University Third Hospital
Early Phase 1
9
Beijing
2023-09-12
Recruiting
Peking Union Medical College Hospital
Not applicable
40
Beijing
2023-09-12
Recruiting
Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery
NCT06030804Elderly, Cancer Surgery, Dexmedetomidine, Long-Term Survivors
DrugDexmedetomidine
Peking University First Hospital
Not applicable
4,532
Hefei, Beijing, Chongqing, Fuzhou, Jinjiang, Guangzhou, Shenzhen, Nanning
2023-09-12
Active, closed
Bristol-Myers Squibb
Phase 3
774
Beijing, Xiamen, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Changsha, Hohhot
2023-09-11
Recruiting
Tasly Pharmaceutical Group Co., Ltd
Phase 3
408
Beijing, Lanzhou, Shijiazhuang, Luoyang, Wuhan, Suzhou, Nanchong, Tianjin
2023-09-11
Active, closed
Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD
NCT06707753Wet Age-related Macular Degeneration (wAMD)
DrugAL-001
Beijing Anlong Biopharmaceutical Co., Ltd.
Phase 1/2
21
Beijing
2023-09-11
Recruiting
AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
NCT06035250Gastric Cancer, Image, Pathology
Chinese Academy of Sciences
Observational
200
Beijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai
2023-09-10
Active, closed
Peking University People's Hospital
Phase 2
30
Beijing
2023-09-10
Active, closed
Effect of Low-dose Esketamine on Maternal Depression at 3 Years After Childbirth
NCT05698394Prenatal Depression, Ketamine, Postpartum Depression
DrugEsketamine
Peking University First Hospital
Phase 4
364
Changsha, Nanjing, Hangzhou, Beijing
2023-09-09
Recruiting
Hoffmann-La Roche
Phase 3
230
Baoding, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Jinan
2023-09-08
Recruiting
Gilead Sciences
Phase 3
402
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei
2023-09-07
Active, closed
Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis with Translocation (11;14)
NCT05996406Light Chain (AL) Amyloidosis, CCND1 Translocation, Venetoclax
DrugsVenetoclax·Dexamethasone
Peking Union Medical College Hospital
Phase 2
36
Beijing
2023-09-07
Recruiting
Chinese PLA General Hospital
Phase 1/2
30
Beijing
2023-09-06
Recruiting
SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC
NCT06457906Small-cell Lung Cancer, Brain Metastases, SRS, Stereotactic Radiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
340
Beijing
2023-09-01
Active, closed
Chinese PLA General Hospital
Observational
100
Beijing
2023-09-01
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
181
Beijing
2023-09-01
Not yet open
Chinese PLA General Hospital
Not applicable
98
Beijing
2023-09-01
Recruiting
Chinese Academy of Sciences
Observational
400
Beijing, Changsha
2023-09-01
Recruiting
Peking Union Medical College Hospital
Observational
10,000
Beijing
2023-09-01
Not yet open
Fluorescence Laparoscopic Navigation for Rectal Cancer and Sigmoid Colon Cancer
NCT05730595Colorectal Neoplasms, Fluorescence, Lymph Node Excision
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
550
Hefei, Beijing, Chengdu, Fuzhou, Guangzhou, Shijiazhuang, Haerbin, Nanjing
2023-09-01
Not yet open
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
NCT06041490Liver Transplant; Complications, Hepatocarcinoma, Recurrent Osteosarcoma, High-Risk Cancer
DrugBevacizumab
Peking Union Medical College Hospital
Phase 2
88
Beijing
2023-09
Active, closed
Janssen Research & Development, LLC
Phase 3
420
Beijing, Changchun, Chengdu, Guangzhou, Jinan, Ningbo, Shenyang, Wuhan
2023-08-31
Recruiting
The Effects of Anesthetics on Brain Network Connectivity in Patients With Supratentorial Glioma
NCT06138340Brain Network Connectivity, Postoperative Delirium, Dexmedetomidine, Propofol
DrugsRemimazolam·Propofol·Dexmedetomidine
Beijing Tiantan Hospital
Observational
120
Beijing
2023-08-31
Recruiting
Peking Union Medical College Hospital
Phase 4
120
Beijing
2023-08-31
Recruiting
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Phase 4
1,312
Huainan, Beijing, Xiamen, Guangzhou, Shenzhen, Nanning, Shijiazhuang, Tangshan
2023-08-31
Active, closed
Cytokinetics
Phase 3
500
Guangzhou, Beijing, Jilin City, Nanjin, Shanghai, Shenyang, Wuhan, Xi'an
2023-08-31
Not yet open
Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections
NCT05988177Carbapenem Resistant Bacterial Infection, Hemophagocytic Lymphohistiocytoses
Beijing Friendship Hospital
Not applicable
20
Beijing
2023-08-30
Recruiting
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
NCT05966467Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD
Alexion Pharmaceuticals, Inc.
Observational
200
Beijing, Guangzhou, Henan, Shanghai, Sichuan, Wuhan
2023-08-30
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
500
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Nanchang, Shanghai
2023-08-28
Active, closed
Hoffmann-La Roche
Observational
1,000
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Haikou, Hohhot
2023-08-25
Recruiting
Xuanwu Hospital, Beijing
Not applicable
472
Beijing
2023-08-25
Recruiting
AstraZeneca
Phase 3
231
Beijing, Changchun, Hohhot, Lanzhou, Nanjing, Shanghai, Shenyang, Shenzhen
2023-08-24
Recruiting
Haihe Biopharma Co., Ltd.
Phase 1/2
141
Beijing, Fuzhou, Guangzhou, Zhengzhou, Changsha, Shanghai, Chengdu
2023-08-22
Active, closed
Pfizer
Phase 2
507
Beijing, Fuzhou, Dongguan, Guangzhou, Shijiazhuang, Changsha, Wuhan, Nanchang
2023-08-22
Active, closed
Han Ying
Phase 2/3
184
Lanzhou, Guangzhou, Nanjing, Shenyang, Xi'an, Yan’an, Kunming, Beijing
2023-08-21
Recruiting
AstraZeneca
Observational
52,121
Beijing, Changsha, Chengdu, Guangzhou, Wuhan
2023-08-21
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
DrugDS-3939a
Daiichi Sankyo
Phase 1/2
590
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Jinan, Nanchang, Neijiang
2023-08-18
Recruiting
TYK Medicines, Inc
Phase 2
420
Beijing
2023-08-17
Active, closed
Amgen
Phase 4
36
Beijing, Fuzhou, Guangzhou, Harbin, Xi'an, Hangzhou
2023-08-17
Recruiting
DualityBio Inc.
Phase 1/2
862
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Baoding, Harbin
2023-08-17
Active, closed
Sun Yat-sen University
Not applicable
620
Beijing, Fuzhou, Lanzhou, Dongguan, Foshan, Guangzhou, Wuhan, Nanjing
2023-08-16
Recruiting
Shandong Boan Biotechnology Co., Ltd
Phase 1
78
Beijing
2023-08-16
Active, closed
Novartis Pharmaceuticals
Phase 2
41
Wuhan, Beijing, Jinan
2023-08-16
Recruiting
Peking Union Medical College
Phase 2
39
Beijing
2023-08-15
Recruiting
Jun Guo
Phase 1/2
50
Beijing
2023-08-15
Not yet open
KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma
NCT05985707HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer
DrugsKN046·KN026·Xelox
Peking University Cancer Hospital & Institute
Phase 2
80
Beijing
2023-08-15
Recruiting
Beijing Continent Pharmaceutical Co, Ltd.
Phase 3
248
Beijing, Shanghai, Bengbu, Changsha, Chongqing, Guizhou, Hangzhou, Henan
2023-08-12
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
364
Hefei, Beijing, Chongqing, Nanning, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2023-08-11
Active, closed
Pfizer
Phase 3
59
Beijing, Guangzhou, Wuhan, Xi'an
2023-08-09
Active, closed
Hoffmann-La Roche
Phase 3
459
Beijing, Cangzhou Shi, Shijiazhuang, Wuxi, Changzhou, Chengdu, Guangzhou, Hangzhou
2023-08-08
Recruiting
A Phase I/II Clinical Study in Patients with Advanced Solid Tumor.
NCT05970016Patients with Advanced Solid Tumors
Beijing Tide Pharmaceutical Co., Ltd
Phase 1/2
56
Beijing
2023-08-07
Recruiting
The Beijing Longitudinal Disability Survey in Community Elderly
NCT06863727Ageing, Disability, Cognitive Impairment, Frailty
Xuanwu Hospital, Beijing
Observational
1,962
Beijing
2023-08-07
Active, closed
CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
NCT05896124Primary Biliary Cholangitis (PBC)
DrugPleacbo
Cascade Pharmaceuticals, Inc
Phase 2
75
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Zhenjiang, Changchun
2023-08-07
Recruiting
Capital Medical University
Observational
500
Beijing
2023-08-07
Active, closed
Cascade Pharmaceuticals, Inc
Phase 2
50
Hefei, Beijing, Wuhan, Changsha, Changchun, Jinan, Shanghai, Hangzhou
2023-08-07
Active, closed
RemeGen Co., Ltd.
Phase 2/3
201
Beijing
2023-08-04
Recruiting
Tong Chen, MD
Phase 1/2
30
Hefei, Beijing, Fuzhou, Zhengzhou, Shanghai
2023-08-03
Recruiting
Peking University People's Hospital
Phase 3
218
Beijing, Guangzhou
2023-08-03
Recruiting
AskGene Pharma, Inc.
Phase 1/2
594
Beijing, Shanghai
2023-08-02
Recruiting
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05924750Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
DrugBL-M11D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
130
Hefei, Beijing, Haerbin, Shenyang, Jinan, Shanghai, Chengdu, Tianjin
2023-08-02
Recruiting
Peijia Medical Technology (Suzhou) Co., Ltd.
Not applicable
116
Beijing, Fuzhou, Xiamen, Guangzhou, Guangdong, Haerbin, Wuhan, Changsha
2023-08-01
Recruiting
China-Japan Friendship Hospital
Phase 4
146
Beijing
2023-08-01
Active, closed
Sun Yat-sen University
Phase 3
490
Bengbu, Hefei, Beijing, Fuzhou, Dongguan, Guangzhou, Zhongshan, Nanning
2023-08-01
Active, closed
Young Patients With Early Breast Cancer
NCT06027541Breast Cancer Female
Peking Union Medical College Hospital
Observational
1,000
Beijing
2023-08-01
Active, closed
Bio-Thera Solutions
Phase 2
162
Baotou, Beijing, Changsha, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou
2023-08-01
Recruiting
Beijing Children's Hospital
Observational
2,600
Beijing
2023-08-01
Recruiting
Xiang Yang Zhang
Not applicable
50
Hefei, Beijing
2023-08-01
Recruiting
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life
NCT05991128Heart Failure With Preserved Ejection Fraction, Iron Deficiencies, Acute Heart Failure
DrugFerric Derisomaltose
China-Japan Friendship Hospital
Phase 4
170
Beijing
2023-08-01
Active, closed
GeneCradle Inc
Phase 1/2
33
Beijing, Chengdu, Chongqing, Wuhan
2023-08-01
By invitation
Osteo Match Cages Versus PEEK Cages in Osteoporotic Patients
NCT05981222Osteoporosis, Degenerative Lumbar Disease, Degeneration Spine
Peking University Third Hospital
Observational
1,500
Beijing
2023-08-01
Recruiting
Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection
NCT06135922EBV-associated Hemophagocytic Lymphohistiocytosis, EBV Infection
Chinese PLA General Hospital
Phase 1
9
Beijing
2023-08-01
Recruiting
GlaxoSmithKline
Phase 3
892
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2023-08-01
Recruiting
Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT
NCT06119256EBV Infection After Allogenic HSCT
Chinese PLA General Hospital
Phase 1
12
Beijing
2023-08-01
Recruiting
Chinese PLA General Hospital
Phase 2
200
Beijing
2023-08-01
Recruiting
Real-world of AI in Diagnosing Retinal Diseases
NCT05981950Artificial Intelligence, Retinal Diseases
Beijing Tongren Hospital
Observational
100,000
Beijing
2023-08-01
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Observational
380
Beijing, Tianjin
2023-08
Active, closed
HOYA Lens Thailand LTD.
Not applicable
249
Beijing, Guangzhou, Shanghai, Shengyang, Tianjin
2023-07-31
Recruiting
Peking University Third Hospital
Not applicable
156
Beijing
2023-07-30
Not yet open
Shanghai MicroPort CardioFlow Medtech Co., Ltd.
Observational
89
Beijing, Chengdu, Hangzhou, Shanghai
2023-07-30
Active, closed
Belite Bio, Inc
Phase 3
429
Beijing, Chengdu, Guandong, Zhejiang
2023-07-27
Active, closed
AbbVie
Phase 3
1,014
Bengbu, Beijing, Xiamen, Guangzhou, Shantou, Nanning, Luoyang, Wuhan
2023-07-25
Recruiting
Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital Biomarkers
NCT07392411Parkinson's Disease, Progressive Supranuclear Palsy(PSP), Multiple System Atrophy, Healthy Control
Beijing Tiantan Hospital
Observational
720
Beijing
2023-07-25
Recruiting
Beijing Union Pharmaceutical Factory Ltd
Phase 3
504
Beijing
2023-07-25
Recruiting
Incyte Corporation
Phase 1
570
Beijing, Hangzhou
2023-07-24
Recruiting
Beijing Union Pharmaceutical Factory Ltd
Phase 3
410
Beijing
2023-07-24
Recruiting
Shanghai JMT-Bio Inc.
Phase 3
880
Beijing
2023-07-23
Recruiting
Study of VEGF-A Targeting NIR-II Fluorescence Endoscopy in the Gastrointestinal Tract
NCT06430372Gastrointestinal Carcinoma, Dysplasia, Gastrointestinal Polyp
Institute of Automation, Chinese Academy of Sciences
Phase 1
30
Beijing
2023-07-20
Recruiting
Registry of X-linked Adrenoleukodystrophy
NCT05939232X-linked Adrenoleukodystrophy
Beijing Tiantan Hospital
Observational
200
Beijing
2023-07-20
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
102
Beijing
2023-07-20
Recruiting
CNBG-Virogin Biotech (Shanghai) Ltd.
Phase 2
40
Beijing
2023-07-18
Recruiting
Chinese PLA General Hospital
Phase 1/2
30
Beijing
2023-07-15
Recruiting
Chinese PLA General Hospital
Phase 1/2
30
Beijing
2023-07-15
Recruiting
Software Refraction With Mobilerone Versus Retinoscopy
NCT06059521Myopia, Myopia, Moderate, Astigmatism
Beijing Airdoc Technology Co., Ltd.
Not applicable
120
Beijing
2023-07-15
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
1,000
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Zhenjiang, Nanchang
2023-07-11
Recruiting
Surgical Treatment of Irreducible Atlantoaxial Dislocation
NCT05847270Irreducible Atlantoaxial Dislocation
Peking University Third Hospital
Not applicable
70
Beijing
2023-07-11
Recruiting
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
NCT06005493Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
DrugRilvegostomig
AstraZeneca
Phase 1/2
392
Beijing, Shandong
2023-07-11
Active, closed
Novartis Pharmaceuticals
Phase 3
100
Guangzhou, Chengdu, Beijing
2023-07-11
Recruiting
CARsgen Therapeutics Co., Ltd.
Phase 1
20
Beijing, Zhengzhou, Wuhan, Changsha, Shanghai, Xian, Hangzhou
2023-07-11
Recruiting
D3 Bio (Wuxi) Co., Ltd
Phase 1/2
67
Beijing, Guangzhou, Harbin, Wuhan, Shanghai, Chengdu, Hangzhou
2023-07-10
Recruiting
Peking University Third Hospital
Not applicable
60
Beijing
2023-07-10
Active, closed
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2
80
Baotou, Beijing, Changsha, Chengdu, Chongqing, Fuyang, Guangzhou, Hengyang
2023-07-06
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Hefei, Beijing, Foshan, Guangzhou, Shenzhen, Nanning, Guiyang, Wuhan
2023-07-06
Recruiting
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
NCT05631886Solid Tumor, Adult, Lymphoma, EphA2 Overexpression, TP53 R273H
DrugsAbraxane·Ipilimumab·Cyclophosphamide
Chinese PLA General Hospital
Phase 1
10
Beijing
2023-07-04
Recruiting
Beijing Tiantan Hospital
Not applicable
344
Beijing
2023-07-01
Recruiting
Peking University People's Hospital
Observational
756
Beijing
2023-07-01
Recruiting
Peking University First Hospital
Phase 4
70
Beijing
2023-07-01
Recruiting
Peking Union Medical College Hospital
Not applicable
60
Beijing
2023-07-01
Not yet open
The China CardioMyopathy Registry Study
NCT05871632Cardiomyopathies
China National Center for Cardiovascular Diseases
Observational
5,000
Beijing
2023-07-01
Recruiting
Xuanwu Hospital, Beijing
Observational
9,510
Beijing
2023-07-01
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
551
Beijing
2023-06-30
Recruiting
Chinese SLE Treatment And Research Group
Phase 4
40
Beijing
2023-06-29
Active, closed
Hoffmann-La Roche
Phase 3
2,000
Hefei, Beijing, Zunyi, Wuhan, Xuzhou, Pingxiang, Shanghai, Zigong
2023-06-28
Recruiting
Beijing Mabworks Biotech Co., Ltd.
Phase 1/2
132
Beijing
2023-06-28
Active, closed
OncoC4, Inc.
Phase 3
630
Hefei, Beijing, Fuzhou, Xiamen, Dongguan, Guangzhou, Nanning, Haikou
2023-06-28
Active, closed
Peking University Hospital of Stomatology
Phase 2
110
Beijing, Baoding, Tangshan, Harbin, Chifeng, Hohhot, Changchun, Shenyang
2023-06-27
Active, closed
Novartis Pharmaceuticals
Phase 1
123
Beijing, Guangzhou
2023-06-27
Active, closed
Fu Wai Hospital, Beijing, China
Not applicable
36
Beijing, Nanjing
2023-06-26
Recruiting
Sirolimus in the Treatment of Refractory/Relapsed wAIHA
NCT05925023Warm Autoimmune Hemolytic Anemia
DrugSirolimus
Peking Union Medical College Hospital
Not applicable
22
Beijing
2023-06-24
Active, closed
Bristol-Myers Squibb
Phase 3
1,230
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Zhengzhou, Changsha, Nanjing
2023-06-22
Active, closed
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 3
167
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Wuhan, Shenyang, Shanghai, Chengdu
2023-06-20
Recruiting
Study of MHB088C for Patients With Advanced Solid Malignant Tumors
NCT07102004Advanced/Metastatic Solid Tumors
DrugQLC5508
Qilu Pharmaceutical Co., Ltd.
Phase 1/2
515
Beijing
2023-06-20
Recruiting
A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities
NCT07394374Solid Tumors Harboring NTRK Fusion, NTRK, NTRK Gene Fusion, NTRK Fusion Positive
Cullgen (Shanghai),Inc
Phase 1/2
42
Beijing, Chengdu, Guangzhou, Hangzhou, Taiyuan
2023-06-20
Recruiting
Fudan University
Phase 3
764
Beijing, Chongqing, Fuzhou, Guangzhou, Guangdong, Nantong, Yangzhou, Shenyang
2023-06-20
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4
360
Hefei, Beijing, Lanzhou, Nanning, Shijiazhuang, Tianjin, Zhengzhou, Wuhan
2023-06-19
Recruiting
Takeda
Phase 3
408
Hefei, Wuhu, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou, Huizhou
2023-06-16
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
58
Beijing, Fuzhou, Weifang, Shanghai, Taiyuan, Tianjin
2023-06-14
Recruiting
Photoacoustic/Ultrasound Imaging for Breast Nodule Diagnosis, Molecular Classification, and Neoadjuvant Chemotherapy Response Evaluation
NCT06908291Breast Masses, Breast Cancer, Breast Cancer Treated with Neoadjuvant Chemotherapy
Peking Union Medical College Hospital
Not applicable
500
Beijing
2023-06-12
Recruiting
A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
NCT05740956Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostatic Cancer
DrugHS-10502
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
318
Beijing
2023-06-09
Active, closed
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 1/2
84
Beijing, Chengdu, Guangzhou, Jinan, Shanghai, Shenyang, Shijiazhuang, Wuhan
2023-06-09
Recruiting
Hansoh BioMedical R&D Company
Phase 2
170
Beijing, Changsha, Guangzhou, Hangzhou, Nanjing, Shanghai, Tianjin, Zhengzhou
2023-06-08
Recruiting
RemeGen Co., Ltd.
Phase 2
85
Beijing
2023-06-08
Recruiting
Safety and Efficacy of Cera™ Patent Foramen Ovale Occluders.
NCT05774288Patent Foramen Ovale, Cryptogenic Stroke
Lifetech Scientific (Shenzhen) Co., Ltd.
Not applicable
244
Beijing, Guangzhou, Meizhou, Changsha, Changchun, Shenyang, Jinan, Kunming
2023-06-08
Recruiting
Guangzhou JOYO Pharma Co., Ltd
Phase 2/3
210
Beijing
2023-06-06
Active, closed
Eli Lilly and Company
Phase 3
3,127
Hefei, Beijing, Chongqing, Shenzhen, Haikou, Harbin, Luoyang Shi, Zhengzhou
2023-06-05
Recruiting
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
NCT05303519Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3
DrugSafusidenib
Nuvation Bio Inc.
Phase 3
365
Beijing, Fuzhou, Guangzhou, Changsha, Shanghai, Chengdu
2023-06-05
Recruiting
Sound Biopharmaceuticals Ltd.
Phase 1
44
Beijing, Chongqing, Chengdu
2023-06-05
Recruiting
Peking Union Medical College Hospital
Observational
3,705
Beijing
2023-06-04
Active, closed
GeneCradle Inc
Phase 1/2
16
Beijing, Changsha, Hangzhou, Zhengzhou
2023-06-02
Active, closed
ArriVent BioPharma, Inc.
Phase 3
398
Beijing, Meizhou, Xuhui, Hangzhou, Cangzhou, Shushan, Zhengzhou, Changchun
2023-06-01
Active, closed
Health Belief Model-Based Survey on Breast Self-Examination Awareness and Practice Among Community-Dwelling Middle-Aged and Older Women
NCT07149636Breast Neoplasms, Breast Self-Examination, Cancer Screening, Health Belief Model
Peking Union Medical College Hospital
Observational
3,000
Beijing
2023-06-01
Recruiting
Peking Union Medical College Hospital
Phase 2
81
Beijing
2023-06-01
Recruiting
Hoffmann-La Roche
Phase 3
200
Wuhan, XI 'an City, Shaanxi Province, Shanghai, Beijing, Changchun, Chengdu, Guangzhou, Hangzhou
2023-06-01
Active, closed
Biotheus Inc.
Phase 2
50
Beijing, Changchun, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan
2023-06-01
Recruiting
Peking University People's Hospital
Observational
120
Beijing
2023-06-01
Recruiting
Lifetech Scientific (Shenzhen) Co., Ltd.
Not applicable
73
Beijing
2023-06-01
Recruiting
Fudan University
Phase 3
766
Beijing, Chongqing, Fuzhou, Guangzhou, Guangdong, Nantong, Yangzhou, Shenyang
2023-06-01
Recruiting
Chinese PLA General Hospital
Observational
12,567
Beijing
2023-06-01
Recruiting
Peking Union Medical College Hospital
Observational
300
Beijing
2023-06-01
Active, closed
Grand Theravac Life Sciences (Nanjing) Co., Ltd.
Phase 2
80
Beijing
2023-06-01
Recruiting
Chinese PLA General Hospital
Observational
750
Beijing
2023-06
Recruiting
Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC
NCT05917431Unresectable Hepatocellular Carcinoma, Oligometastatic Disease
Peking University Cancer Hospital & Institute
Phase 2
39
Beijing
2023-06
Not yet open
Single Ultra-high Dose Stereotactic Body Radiation Therapy for Early Lung Cancer
NCT05802654Early Lung Cancer, Stereotactic Body Radiotherapy
Peking University Third Hospital
Not applicable
100
Beijing
2023-06
Active, closed
Amgen
Phase 3
509
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Jiangmen, Shijiazhuang, Harbin
2023-05-31
By invitation
Abbisko Therapeutics Co, Ltd
Phase 2
64
Beijing, Chongqing, Fuzhou, Guangzhou, Zhujiang, Wuhan, Hangzhou, Suzhou
2023-05-30
Recruiting
SG1906 for CLDN18.2-Positive Solid Tumors
NCT05857332Locally Advanced Unresectable or Metastatic Solid Tumors
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1
60
Beijing, Xiamen, Guangzhou, Zhengzhou, Shenyang, Taiyuan, Hangzhou
2023-05-30
Recruiting
Beijing Chest Hospital
Phase 4
292
Beijing
2023-05-29
Recruiting
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase 1
60
Beijing
2023-05-29
Recruiting
Peking Union Medical College Hospital
Not applicable
2,478
Beijing, Changchun, Changsha, Changzhou, Chengdu, Dalian, Dongying, Guiyang
2023-05-26
Recruiting
Akeso
Phase 2
78
Beijing, Guangzhou, Wuhan, Jinan, Shanghai, Hangzhou
2023-05-25
Recruiting
China-Japan Friendship Hospital
Phase 4
340
Beijing
2023-05-23
Recruiting
Impact of Erector Spinae Plane Block on Chronic Postsurgical Pain in Breast Cancer Patients
NCT05494502Breast Neoplasms, Mastectomy, Nerve Block, Dexmedetomidine
Peking University First Hospital
Not applicable
1,206
Beijing
2023-05-23
Recruiting
Pfizer
Phase 3
318
Hefei, Beijing, Dongguan, Guangzhou, Cangzhou, Changsha, Nanjing, Nanchang
2023-05-20
Recruiting
Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study
NCT05860400Coronary Artery Disease, Coronary Artery Stenosis, Coronary Artery Restenosis, Coronary Artery Disease Progression
Peking Union Medical College Hospital
Observational
39
Beijing
2023-05-17
Recruiting
Takeda
Phase 3
240
Beijing, Zhengzhou, Changsha, Shanghai, Hangzhou
2023-05-16
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
230
Hefei, Beijing, Xiamen, Xinxiang, Zhengzhou, Huai'an, Shanghai, Hangzhou
2023-05-16
Recruiting
Peking Union Medical College Hospital
Observational
235
Beijing
2023-05-15
Recruiting
LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer
NCT05923255Hepatic Flexure Colon Cancer, Proximal Transverse Colon Cancer
Zhejiang University
Not applicable
568
Bengbu, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Wuhan, Changsha
2023-05-14
Active, closed
Peking University Third Hospital
Not applicable
80
Beijing
2023-05-12
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2
60
Beijing
2023-05-11
Recruiting
Intensive Treatment on Periodontitis in Aortic Stenosis
NCT06587971Aortic Valve Stenosis, Periodontitis
China National Center for Cardiovascular Diseases
Not applicable
920
Beijing
2023-05-10
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
480
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning
2023-05-10
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
NCT06565689Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
DrugYK012
Excyte Biopharma Ltd
Phase 1
48
Beijing
2023-05-09
Recruiting
Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy
NCT05839314Nephropathy, Glomerular Diseases, Idiopathic Membranous Nephropathy
DrugHuaier
Chinese PLA General Hospital
Phase 4
480
Beijing
2023-05-09
Active, closed
Gilead Sciences
Phase 3
654
Anhui, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fujian, Fuzhou
2023-05-08
Active, closed
AstraZeneca
Phase 3
37
Beijing, Chongqing, Yangzhou, Zhengzhou
2023-05-08
Recruiting
Keymed Biosciences Co.Ltd
Phase 2
70
Beijing
2023-05-08
Active, closed
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2
63
Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Fuxin, Shenyang
2023-05-05
Active, closed
Novartis Pharmaceuticals
Phase 2
63
Wuhan, Nanjing, Shenyang, Xian, Chengdu, Hangzhou, Beijing, Guangzhou
2023-05-05
Recruiting
Frontline of ASCT in High-risk DLBCL
NCT05831865Diffuse Large B Cell Lymphoma
Peking University People's Hospital
Observational
175
Beijing
2023-05-03
Recruiting
Chinese PLA General Hospital
Phase 2
10
Beijing
2023-05-01
Recruiting
Li An
Observational
365
Beijing
2023-05-01
Active, closed
Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
NCT07018427Breast Neoplasms, Triple Negative Breast Cancer, HR+, HER2-, Advanced Breast Cancer, Breast Cancer
DrugSacituzumab Govitecan
Peking University Cancer Hospital & Institute
Observational
70
Beijing
2023-05-01
Recruiting
Beijing Friendship Hospital
Observational
407
Beijing
2023-05-01
Recruiting
Xuanwu Hospital, Beijing
Observational
458
Beijing
2023-05-01
Not yet open
Suzhou Puhe Pharmaceutical Technology Co., LTD
Phase 3
350
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou
2023-05-01
Recruiting
Beijing Tongren Hospital
Phase 3
272
Beijing
2023-05-01
Not yet open
Peking Union Medical College Hospital
Phase 2
74
Beijing
2023-05
Active, closed
RemeGen Co., Ltd.
Phase 3
318
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou
2023-04-28
Recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2/3
600
Beijing
2023-04-28
Active, closed
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
NCT05804045Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath
DrugPimicotinib
Abbisko Therapeutics Co, Ltd
Phase 3
94
Bengbu, Beijing, Fuzhou, Guangzhou, Guiyang, Zhengzhou, Enshi, Wuhan
2023-04-27
Recruiting
Peking Union Medical College Hospital
Observational
150
Beijing
2023-04-25
Recruiting
Xuanwu Hospital, Beijing
Observational
50,000
Beijing
2023-04-25
Active, closed
AstraZeneca
Phase 2
294
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Harbin, Nanning, Shanghai
2023-04-24
Recruiting
Betta Pharmaceuticals Co., Ltd.
Phase 1
82
Beijing, Baoding, Harbin, Wuhan, Changsha, Changchun, Jinan, Taizhou
2023-04-24
Recruiting
Chinese Academy of Medical Sciences, Fuwai Hospital
Early Phase 1
210
Beijing, Shanghai, Hangzhou
2023-04-24
Recruiting
Peking University Third Hospital
Phase 2
20
Beijing
2023-04-20
Active, closed
Klus Pharma Inc.
Phase 2
356
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-04-19
Recruiting
ZHOU FANGJIAN
Phase 3
298
Beijing, Guangzhou, Hefei, Shanghai, Sichuan, Tianjin, Zhengzhou
2023-04-19
Recruiting
Pfizer
Phase 2
48
Beijing, Guangzhou, Shanghai
2023-04-18
Recruiting
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT05786924Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation
DrugsPanitumumab·Folfox·Cetuximab·Nab-paclitaxel
Institut de Recherches Internationales Servier
Phase 1/2
554
Beijing, Jinan, Shanghai, Suzhou
2023-04-18
Active, closed
BeOne Medicines
Phase 2/3
178
Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning, Guiyang, Shijiazhuang
2023-04-17
Recruiting
Sichuan Jishengtang Pharmaceutical Co., Ltd.
Phase 3
495
Beijing
2023-04-17
Recruiting
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
NCT04124120Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting
Weill Medical College of Cornell University
Not applicable
2,300
Beijing, Changchun, Shanghai, Tianjin
2023-04-17
Recruiting
Akeso
Phase 1/2
87
Beijing
2023-04-14
Active, closed
Hoffmann-La Roche
Phase 2
204
Beijing, Chengdu, Guangzhou, Shanghai
2023-04-13
Active, closed
TrEatment Approach in the Multimodal Era Registry
NCT05629052Chronic Thromboembolic Pulmonary Hypertension, CTEPH
International CTEPH Association
Observational
1,000
Beijing
2023-04-12
Recruiting
Qilu Hospital of Shandong University
Phase 4
2,600
Bozhou, Chuzhou, Hefei, Beijing, Zunyi, Zhengzhou, Dalian, Xining
2023-04-12
Active, closed
Janssen Research & Development, LLC
Phase 3
20,284
Beijing, Cangzhou, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Daqing
2023-04-11
Recruiting
China National Center for Cardiovascular Diseases
Phase 4
202
Beijing
2023-04-11
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2
300
Beijing, Guangzhou, Luoyang, Hengshui, Daqing, Wuhan, Baotou, Huai'an
2023-04-06
Active, closed
Lepu Biopharma Co., Ltd.
Phase 2
238
Beijing, Chongqing, Fuzhou, Guangzhou, Maoming, Shantou, Shaoguan, Zhongshan
2023-04-06
Recruiting
Shanghai Miracogen Inc.
Phase 3
290
Beijing
2023-04-06
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2
368
Beijing, Chongqing
2023-04-04
Recruiting
Nanfang Hospital, Southern Medical University
Phase 4
7,188
Hefei, Huainan, Suzhou, Beijing, Chongqing, Foshan, Guangzhou, Zhongshan
2023-04-03
Active, closed
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
NCT05631899Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V, KRAS G12C
DrugsAbraxane·Ipilimumab·Cyclophosphamide
Chinese PLA General Hospital
Phase 1
9
Beijing
2023-04-03
Active, closed
Sanofi
Phase 2
999
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jingzhou
2023-04-03
Active, closed
Bayer
Phase 3
985
Beijing, Wuhan, Changsha, Nanjing, Shanghai, Chengdu, Tianjin, Hangzhou
2023-04-03
Recruiting
Peking University People's Hospital
Phase 2
38
Beijing
2023-04-01
Recruiting
Peking Union Medical College Hospital
Not applicable
42
Beijing
2023-04-01
Not yet open
Shanghai JMT-Bio Inc.
Phase 3
146
Beijing
2023-04
Not yet open
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
38
Beijing
2023-04
Recruiting
AstraZeneca
Phase 3
4,300
Baoding, Beijing, Changchun, Changsha, Chengdu, Chifeng, Dalian, Foshan
2023-03-31
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
1,946
Beijing, Guangzhou, Suining
2023-03-30
Recruiting
Peking Union Medical College Hospital
Not applicable
40
Beijing
2023-03-30
Active, closed
Janssen Research & Development, LLC
Phase 3
614
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2023-03-29
Recruiting
Peking University Cancer Hospital & Institute
Phase 3
472
Beijing
2023-03-29
Recruiting
China-Japan Friendship Hospital
Phase 4
336
Beijing, Baoding, Qinhuangdao, Gongyi, Yangzhou, Jining, Qingdao, Changzhi
2023-03-29
Recruiting
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
NCT06041776Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy
Betta Pharmaceuticals Co., Ltd.
Phase 3
570
Beijing, Nanjing, Shanghai
2023-03-28
Recruiting
A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
NCT05718895Advanced/Metastatic Solid Tumors
DrugATG-022
Antengene Biologics Limited
Phase 1
156
Beijing, Chengdu, Fuzhou, Hefei, Jinan, Lanzhou, Qingdao, Shanghai
2023-03-27
Recruiting
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
220
Beijing, Chongqing, Fuzhou, Nanning, Harbin, Luoyang, Zhengzhou, Changsha
2023-03-27
Recruiting
China-Japan Friendship Hospital
Not applicable
100
Beijing
2023-03-27
Active, closed
Beijing Tongren Hospital
Not applicable
572
Beijing
2023-03-26
Recruiting
LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With ASCVD (TARGET OLD)
NCT05765370Atherosclerotic Cardiovascular Disease, Older Patients, LDL Cholesterol
China National Center for Cardiovascular Diseases
Not applicable
4,200
Beijing
2023-03-24
Recruiting
F573 for Injection for the Treatment of Liver Injury/Failure
NCT05689645Acute Liver Failure, Acute-On-Chronic Liver Failure
Beijing Continent Pharmaceutical Co, Ltd.
Phase 2
97
Beijing, Qingyuan, Shiyan, Huaihua, Pingxiang, Changchun, Binzhou, Heze
2023-03-24
Active, closed
SeQuent ® Please CIS for the Treatment of INtracranial Atherosclerotic Stenosis
NCT06047964Stroke, Intracranial Atherosclerotic Stenosis
B. Braun Medical International Trading Company Ltd.
Not applicable
281
Beijing, Harbin, Nanyang, Changchun, Jining, Qingdao, Shanghai, Taiyuan
2023-03-23
Active, closed
Janssen Research & Development, LLC
Phase 3
1,135
Beijing, Changchun, Changsha, Chengdu, Chongqing, Deyang, Guangzhou, Hangzhou
2023-03-23
Recruiting
Peking University Cancer Hospital & Institute
Phase 3
140
Beijing
2023-03-21
Recruiting
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 1
51
Beijing
2023-03-20
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Beijing, Chongqing, Guangzhou, Guiyang, Haikou, Zhengzhou, Wuhan, Changsha
2023-03-16
Recruiting
Teligene US
Phase 2
60
Beijing, Chongqing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2023-03-16
Active, closed
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1/2
725
Beijing, Changsha, Fuzhou, Guangzhou, Hangzhou, Ha’erbin, Hefei, Jinan
2023-03-15
Active, closed
AbbVie
Phase 3
520
Bengbu, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-03-15
Recruiting
Chinese SLE Treatment And Research Group
Phase 4
40
Beijing
2023-03-09
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
191
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Zhengzhou
2023-03-09
Recruiting
OH2 Injection in Melanoma
NCT05868707Melanoma
DrugOH2
Binhui Biopharmaceutical Co., Ltd.
Phase 3
340
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang, Harbin
2023-03-08
Active, closed
Pfizer
Phase 3
624
Hefei, Beijing, Fuzhou Fujian, Foshan, Guangzhou, Nanning, Harbin, Luoyang
2023-03-03
Recruiting
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 1
52
Zhengzhou, Shijiazhuang, Hangzhou, Beijing, Shanghai
2023-03-02
Recruiting
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
NCT06410651Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
53
Beijing
2023-03-01
Recruiting
Nova Therapeutics LLC
Phase 1
20
Beijing
2023-03-01
Recruiting
Beijing Chao Yang Hospital
Observational
100
Beijing
2023-03-01
Recruiting
A Clinical Study of Fundus OCTA for the Identification of CMD
NCT05743140Coronary Microvascular Disease
Peking University First Hospital
Observational
400
Beijing
2023-03-01
Recruiting
Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
NCT06429839Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
55
Beijing
2023-03-01
Not yet open
Peking University First Hospital
Observational
2,000
Hefei, Beijing, Chongqing, Zhengzhou, Shanghai
2023-03
Rows per page Showing 4001–4500 of 5576
Previous 7 8 9 10 11 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 November 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=9

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 09 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,576 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,389 of the 5,576 studies on this page are recruiting new participants as of the 09 Nov 2026, 03:17 UTC sync. A further 990 have not yet opened recruitment, 1,019 are active but closed to new participants, and 178 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.